Equities research analysts predict that K2M Group Holdings, Inc. (NASDAQ:KTWO) will announce sales of $65.57 million for the current fiscal quarter, Zacks Investment Research reports. Three analysts have made estimates for K2M Group’s earnings, with estimates ranging from $65.30 million to $66.00 million. K2M Group posted sales of $61.79 million during the same quarter last year, which would indicate a positive year-over-year growth rate of 6.1%. The business is scheduled to issue its next quarterly earnings results on Monday, March 5th.

On average, analysts expect that K2M Group will report full-year sales of $65.57 million for the current financial year, with estimates ranging from $255.60 million to $265.50 million. For the next year, analysts forecast that the business will report sales of $283.38 million per share, with estimates ranging from $281.60 million to $286.20 million. Zacks Investment Research’s sales averages are an average based on a survey of sell-side analysts that that provide coverage for K2M Group.

K2M Group (NASDAQ:KTWO) last released its earnings results on Wednesday, November 1st. The medical device company reported ($0.20) EPS for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.01). K2M Group had a negative return on equity of 16.02% and a negative net margin of 16.22%. The company had revenue of $62.65 million during the quarter, compared to analysts’ expectations of $62.69 million. During the same period in the prior year, the company posted ($0.19) earnings per share. The company’s revenue was up 5.6% on a year-over-year basis.

KTWO has been the topic of a number of recent research reports. Piper Jaffray Companies reissued an “overweight” rating and issued a $28.00 target price on shares of K2M Group in a research note on Tuesday, October 10th. Oppenheimer set a $24.00 target price on K2M Group and gave the stock a “buy” rating in a research note on Wednesday, October 18th. Royal Bank Of Canada reissued a “buy” rating and issued a $26.00 target price on shares of K2M Group in a research note on Friday, September 22nd. Zacks Investment Research raised K2M Group from a “hold” rating to a “buy” rating and set a $25.00 price objective on the stock in a research report on Wednesday, October 4th. Finally, Wells Fargo & Company dropped their price objective on K2M Group from $28.00 to $23.00 and set an “outperform” rating on the stock in a research report on Tuesday, October 10th. One research analyst has rated the stock with a sell rating, one has given a hold rating, ten have issued a buy rating and one has assigned a strong buy rating to the company’s stock. K2M Group currently has an average rating of “Buy” and a consensus target price of $25.00.

Institutional investors have recently added to or reduced their stakes in the stock. BNP Paribas Arbitrage SA boosted its position in shares of K2M Group by 5,175.3% during the second quarter. BNP Paribas Arbitrage SA now owns 4,484 shares of the medical device company’s stock valued at $109,000 after buying an additional 4,399 shares during the last quarter. Cubist Systematic Strategies LLC boosted its position in shares of K2M Group by 7,765.0% during the third quarter. Cubist Systematic Strategies LLC now owns 4,719 shares of the medical device company’s stock valued at $100,000 after buying an additional 4,659 shares during the last quarter. Rockefeller Financial Services Inc. bought a new position in K2M Group in the third quarter valued at about $105,000. Legal & General Group Plc lifted its holdings in K2M Group by 9.1% in the first quarter. Legal & General Group Plc now owns 6,763 shares of the medical device company’s stock valued at $138,000 after acquiring an additional 564 shares during the period. Finally, Dorsey & Whitney Trust CO LLC bought a new position in K2M Group in the second quarter valued at about $211,000. 98.22% of the stock is currently owned by institutional investors.

Shares of K2M Group (KTWO) opened at $18.93 on Friday. K2M Group has a 12 month low of $17.23 and a 12 month high of $25.99. The company has a debt-to-equity ratio of 0.29, a quick ratio of 1.67 and a current ratio of 3.06.

ILLEGAL ACTIVITY NOTICE: This news story was posted by American Banking News and is the sole property of of American Banking News. If you are reading this news story on another publication, it was illegally copied and reposted in violation of U.S. and international copyright and trademark law. The legal version of this news story can be read at https://www.americanbankingnews.com/2017/12/03/65-57-million-in-sales-expected-for-k2m-group-holdings-inc-ktwo-this-quarter-2.html.

About K2M Group

K2M Group Holdings, Inc is a medical device company focused on designing, developing and commercializing spine and minimally invasive technologies and techniques. The Company’s solutions are focused on achieving three-dimensional Total Body Balance. Its spine products are used by spine surgeons to treat spinal pathologies, such as deformity (primarily scoliosis), trauma and tumor.

Get a free copy of the Zacks research report on K2M Group (KTWO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for K2M Group (NASDAQ:KTWO)

Receive News & Ratings for K2M Group Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for K2M Group Holdings Inc. and related companies with MarketBeat.com's FREE daily email newsletter.